Thus, the XRCC3 Thr241Met polymorphism might be a potential biomarker to predict clinical outcomes of NSCLC patients treated with platinum-based chemotherapy and a lot of clinical studies have been conducted to evaluate the predictive value of XRCC3 Thr241Met polymorphism[11], [12], [23], [25]. The gene discussed is XRCC3; the disease is non-small cell lung carcinoma.